Meta-Analysis Finds Combination Cream Plus Tranexamic Acid Effective for Melasma

<?xml version="1.0" encoding="UTF-8"?>
<!--$RCSfile: InCopy_agile.xsl,v $ $Revision: 1.35 $-->
<!--$RCSfile: drupal.xsl,v $ $Revision: 1.7 $-->
<root generator="drupal.xsl" gversion="1.7"> <header> <fileName>168499</fileName> <TBEID>0C050AD1.SIG</TBEID> <TBUniqueIdentifier>MD_0C050AD1</TBUniqueIdentifier> <newsOrJournal>News</newsOrJournal> <publisherName>Frontline Medical Communications</publisherName> <storyname/> <articleType>2</articleType> <TBLocation>Published-All Pubs</TBLocation> <QCDate>20240621T143052</QCDate> <firstPublished>20240621T162314</firstPublished> <LastPublished>20240621T162552</LastPublished> <pubStatus qcode="stat:"/> <embargoDate/> <killDate/> <CMSDate>20240621T162314</CMSDate> <articleSource/> <facebookInfo>if you cannot find this story to link, subcutaneous is misspelled in the headline https://www.mdedge.com/dermatology/article/26</facebookInfo> <meetingNumber/> <byline>Shilpa Chugh Garcha</byline> <bylineText>SHILPA CHUGH GARCHA</bylineText> <bylineFull>SHILPA CHUGH GARCHA</bylineFull> <bylineTitleText/> <USOrGlobal/> <wireDocType/> <newsDocType/> <journalDocType/> <linkLabel/> <pageRange/> <citation/> <quizID/> <indexIssueDate/> <itemClass qcode="ninat:text"/> <provider qcode="provider:imng"> <name>IMNG Medical Media</name> <rightsInfo> <copyrightHolder> <name>Frontline Medical News</name> </copyrightHolder> <copyrightNotice>Copyright (c) 2015 Frontline Medical News, a Frontline Medical Communications Inc. company. All rights reserved. This material may not be published, broadcast, copied, or otherwise reproduced or distributed without the prior written permission of Frontline Medical Communications Inc.</copyrightNotice> </rightsInfo> </provider> <abstract/> <metaDescription>the use of oral tranexamic acid along with the standard triple combination cream (TCC) reduces melasma severity and recurrence in patients with melasma, without</metaDescription> <articlePDF/> <teaserImage/> <teaser>Tranexamic acid, an antifibrinolytic drug, has shown promise in recent studies, but its optimal use, either alone or as an adjunct to TCC, remains unclear.</teaser> <title>Meta-Analysis Finds Combination Cream Plus Tranexamic Acid Effective for Melasma</title> <deck/> <disclaimer/> <AuthorList/> <articleURL/> <doi/> <pubMedID/> <publishXMLStatus/> <publishXMLVersion>2</publishXMLVersion> <useEISSN>0</useEISSN> <urgency/> <pubPubdateYear/> <pubPubdateMonth/> <pubPubdateDay/> <pubVolume/> <pubNumber/> <wireChannels/> <primaryCMSID/> <CMSIDs/> <keywords/> <seeAlsos/> <publications_g> <publicationData> <publicationCode>skin</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> <publicationData> <publicationCode>fp</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> <publicationData> <publicationCode>im</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> <publicationData> <publicationCode>ob</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> </publications_g> <publications> <term canonical="true">13</term> <term>15</term> <term>21</term> <term>23</term> </publications> <sections> <term>53</term> <term canonical="true">39313</term> </sections> <topics> <term canonical="true">276</term> <term>177</term> <term>203</term> <term>27442</term> </topics> <links/> </header> <itemSet> <newsItem> <itemMeta> <itemRole>Main</itemRole> <itemClass>text</itemClass> <title>Meta-Analysis Finds Combination Cream Plus Tranexamic Acid Effective for Melasma</title> <deck/> </itemMeta> <itemContent> <h2>TOPLINE:</h2> <p>A meta-analysis showed that <span class="tag metaDescription">the use of oral tranexamic acid along with the standard triple combination cream (TCC) reduces melasma severity and recurrence in patients with melasma, without increasing toxicity</span>.</p> <h2>METHODOLOGY:</h2> <ul class="body"> <li>Current treatments for melasma focus on inducing remission and preventing relapse. Tranexamic acid, an antifibrinolytic drug, has shown promise in recent studies, but its optimal use, either alone or as an adjunct to TCC, remains unclear.</li> <li>Researchers conducted a meta-analysis of four randomized controlled trials patients that compared oral tranexamic acid plus TCC (hydroquinone, retinoic acid, and hydrocortisone) and TCC alone in 480 patients with melasma, divided almost evenly into the two treatment groups.</li> <li>The main outcome was the change in the Melasma Severity Area Index (MASI) score and recurrence rate from baseline.</li> </ul> <h2>TAKEAWAY:</h2> <ul class="body"> <li>Patients treated with oral tranexamic acid plus TCC showed a greater reduction in MASI scores compared with those who received TCC alone (mean difference, −3.10; <em>P </em>= .03).</li> <li>The recurrence rate of melasma was significantly lower in the tranexamic acid plus TCC group (risk ratio [RR], 0.28; <em>P</em> &lt; .001).</li> <li>There was no significant difference in the incidences of erythema (RR, 0.63; <em>P</em> = .147) and burning (RR, 0.59; <em>P</em> = .131).</li> </ul> <h2>IN PRACTICE:</h2> <p>“Evidence indicates that oral tranexamic acid confers clinical benefits, contributing to the enhancement of treatment outcomes in melasma when used in conjunction with TCC therapy,” and results are promising with regards to minimizing recurrence, the authors concluded.</p> <h2>SOURCE:</h2> <p>The study was led by Ocílio Ribeiro Gonçalves, MS, of the Federal University of Piauí, Teresina, Brazil, and was <span class="Hyperlink"><a href="https://academic.oup.com/ced/advance-article-abstract/doi/10.1093/ced/llae226/7689701?redirectedFrom=fulltext&amp;login=false">published online</a></span> on June 8, 2024, in <em>Clinical and Experimental Dermatology</em>.</p> <h2>LIMITATIONS:</h2> <p>There was heterogeneity across studies, including different methods of administration, treatment protocols (including dosage), and timing of treatment.</p> <h2>DISCLOSURES:</h2> <p>The study reported receiving no funding. The authors declared no conflicts of interest.<br/><br/></p> <p> <em>A version of this article appeared on <span class="Hyperlink"><a href="https://www.medscape.com/viewarticle/oral-tranexamic-acid-boosts-melasma-outcomes-topical-2024a1000b6r">Medscape.com</a></span>.</em> </p> </itemContent> </newsItem> <newsItem> <itemMeta> <itemRole>teaser</itemRole> <itemClass>text</itemClass> <title/> <deck/> </itemMeta> <itemContent> </itemContent> </newsItem> </itemSet></root>